...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical drug investigation >Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis
【24h】

Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis

机译：莫西沙星在2338例慢性支气管炎急性加重患者中的疗效和耐受性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: A post-marketing surveillance (PMS) study was conducted to evalu ate the efficacy and tolerability of moxifloxacin 400mg once daily in patients with acute exacerbation of chronic bronchitis (AECB) treated by pulmonologists and pulmonary specialists in community-based practice settings.Patient and methods: 2338 patients with AECB (54% male; 46% female) were included in the analysis. PMS studies are prospective, open, uncontrolled and observational in design. All therapeutic decisions were made by the attending physician, based on their clinical practice and experience. This approach was adopted in order to provide valuable information on the safety and efficacy of moxifloxacin therapy in routine clinical practice.Results: The main symptoms of AECB (cough, expectoration, dyspnoea, chest pain and fever) were either resolved or improved in 80-97% of patients. Most patients (65%) improved within 3 days of starting moxifloxacin therapy and 91.6% by day 5. Mean time to improvement was 3.2+-1.6 days. Overall, 96.1% of patients were judged by their physician to be either cured or improved follow ing moxifloxacin therapy. Approximately 57% of patients had previously been treated with an antibiotic for their last episode of AECB. The antibiotics used were mostly macrolides (18.2% of patients), beta-lactams (16.9%), tetracycline/ doxycycline (9.9%) and quinolones (9.5%). The tolerability of moxifloxacin therapy was rated as 'very good' or 'good' in 95.4% of patients. Adverse events were reported in only 1.5% of patients.Conclusion: In conclusion, moxifloxacin 400mg once daily was effective and well tolerated in this group of patients with AECB, combined with a rapid onset of action and a similarly high clinical success rate to that observed in controlled comparative clinical trials.
机译：目的：进行了售后监测（PMS）研究，以评估肺炎专家和肺部专家在社区实践环境中每天400 mg莫西沙星在慢性支气管急性加重（AECB）患者中的疗效和耐受性。方法：2338例AECB患者（男性54％;女性46％）被纳入分析。 PMS研究在设计上是前瞻性的，开放的，不受控制的和观察性的。所有治疗决策均由主治医师根据他们的临床实践和经验做出。采用这种方法是为了在常规临床实践中提供有关莫西沙星治疗的安全性和有效性的有价值的信息。结果：80-AECB的主要症状（咳嗽，咳痰，呼吸困难，胸痛和发烧）已得到缓解或改善。 97％的患者。大多数患者（65％）在开始莫西沙星治疗后3天内有所改善，到第5天则为91.6％。平均改善时间为3.2 + -1.6天。总体而言，他们的医师认为96.1％的患者在莫西沙星治疗后已治愈或好转。大约57％的患者先前在其最后一次AECB发作之前接受过抗生素治疗。所使用的抗生素主要是大环内酯类（占患者的18.2％），β-内酰胺类（占16.9％），四环素/强力霉素（占9.9％）和喹诺酮类（占9.5％）。 95.4％的患者将莫西沙星治疗的耐受性评为“非常好”或“很好”。仅有1.5％的患者报告了不良事件。结论：总而言之，每天一次400mg莫西沙星在该组AECB患者中有效且耐受性良好，并且起效迅速，临床成功率与观察到的相似在对照比较临床试验中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号